Metformin treatment in relationship with SARS-CoV-2 disease

Česká verzia

Authors: Andrej Dukát ¹; Ján Gajdošík ²; Milan Kriška ³; Juraj Payer ¹
Authors place of work: V. interná klinika LF UK a UNB, Nemocnica Ružinov, Bratislava ¹; Neštátna ambulancia pre dospelých v Nových Zámkoch ²; Ústav farmakológie a lekárskej farmakológie LF UK v Bratislave ³
Published in the journal: Forum Diab 2022; 11(1): 49-51
Category:

Summary

Epidemy of SARS-CoV-2 infection changed life of all populations in the world and as well as the therapy of diseases in daily clinical praxis. These changes affected also diabetes mellitus. Metformin as the first-line treatment in this group of patients was also influenced with COVID -19. This is the topic of this paper in context of daily clinical practice.

Keywords:

COVID-19 – diabetes mellitus – metformin

Zdroje

1. Kolpin DW. U.S. Geological Survey Research Scientist Recognized for Advancing Exposure Science. Dostupné z WWW: <https://www. usgs.gov/programs/environmental-health-program/science/us-geological-survey-research-scientist-recognized>.
2. Apicella M, Campopiano MC, Mantuano M et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 2020; 8(9): 782–792. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(20)30238–2>.
3. Coppelli A, Giannarelli R, Aragona M et al. Hyperglycemia at hospital admission is associated with severity of the prognosis in patients hospitalized for COVID-19: the Pisa COVID-19 study. Diabetes Care 2020; 43(10): 2345–2348. Dostupné z DOI: <http://dx.doi.org/10.2337/dc20–1380>.
4. Zhu L, She ZG, Cheng X et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab 2020; 31(6): 1068–1077. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmet.2020.04.021>.
5. Bramante CT, Ingraham NE, Murray TA et al. Metformin and risk of mortality in patients hospitalized with COVID-19: a retrospective cohort analysis. Lancet Healthy Longev 2021; 2(1): e34-e41. Dostupné z DOI: <http://dx.doi.org/10.1016/52666–7568(20)30033–7>.
6. Williams DM, Nawaz A, Evans M. Diabetes and Novel Coronavirus Infection: Implications for Treatment. Diabetes Ther 2020; 11(9): 1915–1924. Dostupné z DOI: <http://dx.doi.org/10.1007/s13300–020–00858–2>.
7. Papazafiropoulou A, Antonopoulos S. The COVID-19 pandemic and diabetes mellitus. Arch Med Sci Atheroscler Dis 2020; 5: e200-e205. Dostupné z DOI: <http://dx.doi.org/10.5114/amsad.2020.97435>.
8. Crouse AB, Grimes T, Li P et al. Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes. Front. Endocrinol 11: 600439. Dostupné z DOI: <http://doi: 10.3389/fendo.2020.600439>.
9. Chacra AR. Evolving metformin treatment strategies in type-2 diabetes: from immediate-release metformin monotherapy to extended-release combination therapy. Am J Ther 2014; 21(3): 198–210. Dostupné z DOI: <http://dx.doi.org/10.1097/MJT.0b013e318235f1bb>.
10. Ali S, Fonseca V. Overview of metformin: special focus on metformin extended release. Expert Opin Phramacother 2012; 13(12): 1797–1805. Dostupné z DOI: <http://dx.doi.org/10.1517/14656566.2012.705829>.
11. Idkaldek N, Arafat T, Melhim M et al. Metformin IR versus XR Pharmacokinetics in Humans. J Bioequiv Bioavailab 2011; 3(10): 233–235. Dostupné z DOI: <http://dx.doi.org/10.4172/jbb.1000092>.
12. Timmins P, Donahue S, Meeker J et al. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet 2005; 44(7): 721–729. Dostupné z DOI: <http://dx.doi.org/10.2165/00003088–200544070–00004>.
13. Derosa G, D´Angelo A, Romano D et al. Effects of metformin extended release compared to immediate release formula on glycemic control and glycemic variability in patients with type 2 diabetes. Drug Design Develop Ther 2017; 11: 1481–1488. Dostupné z DOI: <http://dxxxxxx.doi.org/10.2147/DDDT.S131670>.
14. Prídavková D, Šutarík Ľ, Mokáň M. Na forme záleží – výhody metformínu s postupným uvoľňovaním. Forum Diab 2020; 9(3): 177–183.
15. Stepensky D, Friedman M, Srour W et al.: Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. J Control Rel 2001; 71(1): 107–115. Dostupné z DOI: <http://dx.doi.org/10.1016/s0168–3659(00)00374–6>.
16. Marshall SM. 60 years of metformin use: a glance at the past and
a look to the future. Diabetologia 2017; 60(9): 1561–1565. Dostupné
z DOI: <http://dx.doi.org/10.1007/s00125–017–4343-y>.
17. Tucker GT, Casey C, Phillips PJ et al. Metformin kinetics in healthy
subjects and in patients with diabetes mellitus. Br J Clin Pharmacol
1981; 12(2): 235–246. Dostupné z DOI: <http://dx.doi.org/
10.1111/j.1365–2125.1981.tb01206.x>.
18. Jabbour S, Ziring B. Advantages of extended-release metformin
in patients with type 2 diabetes mellitus. Postgrad Med 2011; 123(1):
15–23. Dostupné z DOI: <http://dx.doi.org/10.3810/pgm.2011.01.2241>.
19. Derosa G. Effects of metformin extended release compared to immediate
release formula on glycemic control and glycemic variability
in patients with type 2 diabetes. Drug Design Develop Ther 2017;
11: 1481–1488. Dostupné z DOI: <http://dx.doi.org/10.2147/DDDT.
S131670>.
20. Hug C, Lodish HF. Visfatin: a new adipokine. Science 2005;
307(5708): 366–367. Dostupné z DOI: <http://dx.doi.org/10.1126/
science.1106933>.
21. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein
secreted by visceral fat that mimics the effects of insulin. Science
2005; 307(5708): 426–430. Dostupné z DOI: <http://dx.doi.org/10.1126/
science.1097243>. Retraction in: Science 2007; 318(5850): 565. Dostupné
z DOI: <http://dx.doi.org/10.1126/science.318.5850.565b>.
22. Ruotsalainen E, Vauhkonen I, Salmeniemmi U et al. Markers of endothelial
dysfunction and low-grade inflammation are associated in
the off spring of type 2 diabetic subjects. Atherosclerosis 2008; 197(1):
271–277. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.
2007.04.021>.
23. Schwartz S, Fonseca V, Berner B et al. Efficacy, tolerability, and
safety of a novel once-daily extended-release metformin in patients
with type 2 diabetes. Diabetes Care 2006; 29(4): 759–764. Dostupné
z DOI: <http://dx.doi.org/10.2337/diacare.29.04.06.dc05–1967>.
24. Melikian C, White TJ, Vanderplas A et al. Adherence to oral antidiabetic
therapy in a managed care organization: a comparison of monotherapy,
combination therapy, and fixed-dose combination therapy.
Clin Ther 2002; 24(3): 460–467. Dostupné z DOI: <http://dx.doi.
org/10.1016/s0149–2918(02)85047–0>.
25. Dardano A, Del Prato S. Metformin: an inexpensive and effective
treatment in people with diabetes and COVID-19? Lancet Healthy
Longev 2021; 2(1): e6-e7. Dostupné z DOI: <http://dx.doi.org/10.1016/
S2666–7568(20)30047–7>.
26. Cheng X, Liu YM, Li H et al. Metformin is associated with higher
incidence of acidosis, but not mortality, in individuals with COVID-
19 and pre-existing type 2 diabetes. Cell Metab 2020; 32(4): 537–547.
Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmet.2020.08.013>.